TCM
TEVA icon

Tufton Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Tufton Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-40,328
Closed -$1.34M – 132
2017
Q2 		$1.34M Buy
40,328
+2,295
+6% +$71K 0.27% 68
2017
Q1 		$1.22M Buy
38,033
+585
+2% +$20K 0.24% 69
2016
Q4 		$1.36M Sell
37,448
-2,855
-7% -$114K 0.28% 67
2016
Q3 		$1.85M Buy
40,303
+320
+0.8% +$16.7K 0.37% 67
2016
Q2 		$2.01M Sell
39,983
-2,977
-7% -$158K 0.41% 64
2016
Q1 		$2.3M Sell
42,960
-545
-1% -$32K 0.57% 57
2015
Q4 		$2.86M Sell
43,505
-2,365
-5% -$146K 0.7% 55
2015
Q3 		$2.59M Sell
45,870
-1,380
-3% -$89.5K 0.57% 60
2015
Q2 		$2.79M Sell
47,250
-14,292
-23% -$882K 0.56% 62
2015
Q1 		$3.83M Sell
61,542
-90
-0.1% -$5.23K 0.7% 58
2014
Q4 		$3.54M Sell
61,632
-935
-1% -$52.1K 0.65% 57
2014
Q3 		$3.36M Sell
62,567
-770
-1% -$40.8K 0.63% 59
2014
Q2 		$3.32M Sell
63,337
-193
-0.3% -$9.87K 0.67% 60
2014
Q1 		$3.36M Buy
63,530
+50
+0.1% +$2.31K 0.7% 56
2013
Q4 		$2.54M Buy
+63,480
New +$2.5M 0.54% 67

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Tufton Capital Management's TEVA Position: Q3 2017 in Review

Tufton Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 40,328 shares — an estimated $1.34M sold.

Tufton Capital Management first reported a position in TEVA in Q4 2013 and held it in 15 quarters. The position peaked at $3.83M in Q1 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Tufton Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Tufton Capital Management sold 40,328 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.34M.
  • Tufton Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 15 quarters.
  • Tufton Capital Management's Teva Pharmaceuticals position peaked at $3.83M in Q1 2015.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Tufton Capital Management's 13F filing for Q3 2017, filed 20 Oct 2017.